Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3
1(33.3%)
Phase 2
1(33.3%)
Phase 1
1(33.3%)
3Total
Phase 3(1)
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06263231Phase 3Active Not Recruiting

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

Role: lead

NCT03058289Phase 1Completed

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Role: lead

NCT04781725Phase 2Unknown

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

Role: collaborator

All 3 trials loaded